Navigation Links
Phronetic Technologies Announces First Prenatal Smart Wearable Technology; StimElation is Poised for Production
Date:7/24/2013

Richmond, Virginia (PRWEB) July 24, 2013

Phronetic Technologies, a lean startup formed to commercialize wearable computing solutions, today announced it is one step closer to bringing the first prenatal smart wearable to market. The company has announced plans to launch an Indiegogo campaign, inviting supporters to pre-order StimElation and contribute to the development of this multi-purpose maternity essential.

“We are thrilled about the intrigue that our niche community has shown for StimElation since the evaluation of our conceptual prototypes began in February. We believe that this product will solve four distinct problems that expecting parents encounter during maternity,” said Phronetic Technologies Founder and CEO, Dana Hawes.

“We’ve developed three discreet, smart products to deliver to our customers a comfortable and cost-efficient consumer experience that will mitigate the most prominent concerns of our focus groups. We are confident that the first iteration of these products will resonate positively with early adopters of this technology.”

StimElation is a smart garment designed by a veteran fashion designer who, at the time of final rendering was 29-weeks pregnant. StimElation will be produced in three variations of specialized textiles and electronic functionality. The concept of a smart wearable in the maternity space has piqued the interest of expectant parent groups, medical professionals, manufacturers and distributors of maternity apparel. StimElation has even garnered the intrigue of Kevin Culley, the Director of Innovation at Under Armour, whose External Research team is currently evaluating another Phronetic Technologies wearable for athletes.

Phronetic Technologies has partnered with AiQ, the leadin
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Global Personalized Medicine and Companion Diagnostic Market Q2 2013 - A Strategic Analysis of Industry Trends, Technologies, Participants and Environment Research Report
2. Search Technologies Issues New White Paper Summarizing the Top Ten Applications for the Google Search Appliance
3. Nobles Medical Technologies II's NobleStitch EL Receives Strong Reviews from Physicians at Congenital & Structural Interventions Congress (CSI) in Frankfurt
4. US & Canada Drug Delivery Technologies Industry to Grow at a CAGR of 8.9% by 2017 says a New Research Report at RnRMarketResearch.com
5. Catalent Creates New Advanced Delivery Technologies Business Unit
6. Technologies for monitoring remaining leukemia after treatment may help predict patient outcomes
7. Crawford Technologies Announces New Partnership with Striata
8. Virginia Surgeon Dr. Mark W. McFarland Uses SpineFrontier’s Less Exposure Surgery Technologies: the New Invue Inset Trial-Cage Drill Guide and the Low-Profile Invue Inset
9. Professional and Social Success Characterized the 2nd Global Conference by Dental Implants Leader MIS Implants Technologies Ltd.
10. Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program
11. Global Food Protection Institute Conference to Focus on Innovative Food Protection Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... NJ (PRWEB) , ... August 31, 2015 , ... ... Garden State Urology was formed in 2008, the result of a merger of ... principle that by working cooperatively, they could provide more cost-effective and higher quality ...
(Date:8/31/2015)... ... , ... NJ Top Docs Presents, Dr. Michael Betsy! Dr. Betsy has been reviewed and ... Michael Betsy graduated from Don Bosco Prep in 1990 and was Class Salutatorian. He ... sports in his senior year. He was inducted into the National Honor Society as ...
(Date:8/31/2015)... ... , ... Dr. Stewart Shofner of Shofner Vision Center explains what ... a comprehensive eye examination can diagnose amblyopia. According to the National Eye Institute ... approximately 2 to 3 out of every 100 children. , Dr. Shofner adds, ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... digital marketing communications company announced today that it has officially launched a new ... the new website and brand refresh are more closely aligned with the company’s ...
(Date:8/31/2015)... ... , ... Three Bakers Gluten Free Bakery launched the redesign of its website, ... information on their offering of gluten-free breads and pizzas, living without gluten, and resources ... us to share information about our gluten free product offerings, but also to really ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Three Bakers Gluten Free Bakery Announces Launch of New Website 2
... Scientists have known which genes are linked ... University Baptist Medical Center have organized this information ... in studying the genetics of inflammatory diseases. , ... the researchers were able to systematically map out ...
... Limited,announced today that it will report efficacy data ... once-daily experimental cancer therapy CHR-2797 at the,forthcoming American ... oral aminopeptidase inhibitor currently in clinical development. The,company ... preclinical studies.,Details of the presentations are as follows:, ...
... Specifically for Resource-Limited ... Global Procurement Consortium, UPPSALA, Sweden, November 30 ... an agreement with the Clinton,Foundation HIV/AIDS Initiative (CHAI). Under ... to members of CHAI,s,Procurement Consortium at a discounted price. ...
... Pharmaceuticals is,pleased to announce that it received US ... strengths of 5mg, 10mg, 25mg and 50,mg, effective ... equivalent alternative to Urecholine(R) (a trademark of,Barr Laboratories)., ... Amneal, who is,one of the very first companies ...
... today,announced that the U.S. Drug Enforcement Administration (DEA) ... from,its Auburn, Wash. distribution center effective Dec. 3., ... the Washington facility,and only controlled substance shipments from ... of service to its customers., In an ...
... Smart Solutions to Keep Program,Accessible and Affordable, PHILADELPHIA, ... hosted a panel discussion with local voters to,address the ... the program after scheduled pay cuts go into effect ... the program to find a doctor. But with,Medicare enrollees ...
Cached Medicine News:Health News:Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 3Health News:Cardinal Health Receives DEA Order to Temporarily Cease Distribution of Controlled Substances from Auburn, Wash. Facility 2Health News:AARP Pennsylvania Hosts Panel on Strengthening Medicare 2
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: